Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- (-) Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- (-) Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 66 Results
NPC Releases Updated Guiding Practices to Improve Patient-Centricity in Value Assessments
The Guiding Practices include 33 specific recommendations to ensure value assessments account for the full value pharmaceuticals provide to patients and society
ICER’s UPI Report: Unsupported Policy Information
The 2023 iteration of ICER's Unsupported Price Increase report is misguided at best and harmful to patients and society at worst. NPC outlines why the report should not be used to determine policy or…
NPC’s John O’Brien Talks IRA, Drug Pricing, Patient Costs & Access on The Real Chemistry Podcast
In the latest episode of The Real Chemistry Podcast, NPC President and CEO John M. O'Brien spoke with Real Chemistry’s Founder and Chairman, Jim Weiss, on pressing health policy issues.
NPC Evaluates ICER’s Revised 2023 Value Assessment Framework: A Missed Opportunity for Patients and the Field
The Institute for Clinical and Economic Review (ICER) released its revised value assessment framework. NPC outlines key concerns about the framework and the impact on both patients and those who…
New Research Finds Commercial Health Plans' Use of Prescriber Requirements Doubled and Use of Step Therapy Increased by More Than 31% for Specialty Drug Coverage
New research co-authored by NPC examines how health plan policies have become more restrictive over time.
National Pharmaceutical Council Adds Executive Leaders, Names Dr. Jon Campbell as Chief Science Officer
Michael Pratt named Chief Communications Officer as NPC boosts research and engagement capabilities
Join NPC at ISPOR 2022
Join NPC at ISPOR 2022 for presentations and a student session and visit us at our exhibit booth.
Women Leaders Are Making a Difference
In celebration of Women's History Month, NPC asked our women Board members to share their insights on the importance of having women in leadership and their advice to young leaders.
NPC Chair Shares His Outlook for an Energized Organization
In his first post as Board chair, Mallinckrodt Pharmaceuticals' Dr. Steven Romano says NPC is in a strong position to lead health policy debates through new leadership, dedicated staff experts and an…
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and…
How the Myth of Average Persists in Health Benefits
People are different and their health needs vary. Though differences among patients are common, these differences aren’t always considered in treatment and coverage decisions.
National Pharmaceutical Council Appoints Dr. Sharon Phares as Chief Scientific Officer
NPC announced the appointment of Sharon Phares, PhD, MPH, as Chief Scientific Officer.
Achieving “Fair Access” Requires Better Benefit Design
An Institute for Clinical and Economic Review report acknowledges that patients are still facing barriers to needed treatments as a result of their health benefit design.
Mallinckrodt’s Steven Romano Elected National Pharmaceutical Council Board Chair
NPC announced Steven Romano, MD, Executive Vice President and Chief Scientific Officer, Mallinckrodt Pharmaceuticals, has been elected Chair of NPC’s Board of Directors for 2021-2022.
NPC Commits to Mandating COVID-19 Vaccination
NPC joined a group of 14 health care organizations in and around Washington, D.C., in issuing a joint statement making COVID-19 vaccination a condition of returning to work in their respective…
NPC’s New Leader: Merging Research and Data with Real-World Experience
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
Let’s Work Together to Improve Our Health Care System
NPC's new president and CEO outlines his commitment to working with all partners, across all sectors, to improve our health care system.
National Pharmaceutical Council Appoints John M. O’Brien as President and CEO
Veteran drug pricing and health policy expert John M. O’Brien, Pharm.D., MPH, has been appointed as president and chief executive officer of the National Pharmaceutical Council, effective June 1,…